Famotidine use is not associated with 30-day mortality: a coarsened exact match study in 7158 hospitalized patients with coronavirus disease 2019 from a large …
S Yeramaneni, P Doshi, K Sands, M Cooper… - …, 2021 - gastrojournal.org
Methods Refer to Supplementary Methods for complete details. In brief, admitted adults to
affiliated hospitals who tested positive for SARS-CoV-2 by reverse transcriptase polymerase
chain reaction between February 11, 2020 and May 8, 2020 were included. Exclusion
criteria were death or intubation within 48 hours of admission or if famotidine was received>
24 hours after admission. The primary outcome was 30-day all-cause mortality. Primary
exposure was in-hospital famotidine use, regardless of dose and route, within 24 hours of …
affiliated hospitals who tested positive for SARS-CoV-2 by reverse transcriptase polymerase
chain reaction between February 11, 2020 and May 8, 2020 were included. Exclusion
criteria were death or intubation within 48 hours of admission or if famotidine was received>
24 hours after admission. The primary outcome was 30-day all-cause mortality. Primary
exposure was in-hospital famotidine use, regardless of dose and route, within 24 hours of …